9月20日,国家医保局公布了2025年国家基本医保目录与首版商业健康保险创新药目录(下称“商保目录”)的复评结果,标志着本年度“双目录”调整工作进入关键阶段。此前8月12日,根据初步形式审查结果公示——有534个品种通过国家基本医保目录初审,121款药品入围商保创新药目录。今年是国谈“双目录”的第一年,梳理商保目录的入围药品,能看到一个超预期的现象:121款申报商保目录的产品中,有79款同时通过了...
Source Link9月20日,国家医保局公布了2025年国家基本医保目录与首版商业健康保险创新药目录(下称“商保目录”)的复评结果,标志着本年度“双目录”调整工作进入关键阶段。此前8月12日,根据初步形式审查结果公示——有534个品种通过国家基本医保目录初审,121款药品入围商保创新药目录。今年是国谈“双目录”的第一年,梳理商保目录的入围药品,能看到一个超预期的现象:121款申报商保目录的产品中,有79款同时通过了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.